Key Findings and Conclusions from MARIPOSA-2 Trial

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.